相关实验视频
Updated: May 10, 2026

10:01
In vitro Methylation Assay to Study Protein Arginine Methylation
Published on: October 5, 2014
15.4K
在瘤中使用蛋白质氨酸甲基转移酶抑制剂
Emirhan Harbi1, Christopher E Mason2
1Faculty of Engineering and Natural Sciences, Bahcesehir University, Istanbul, Turkey.
JCO precision oncology
|August 27, 2025
概括
蛋白质氨基甲基转移酶 (PRMT) 是质瘤发展和治疗耐药性的关键因素. 通过破坏瘤生长和提高治疗灵敏度,PRMT抑制剂对治疗质瘤具有前景.
科学领域:
- 神经瘤学
- 表观遗传学
- 癌症生物学
背景情况:
- 质瘤是主要的中枢神经系统 (CNS) 瘤.
- 蛋白质阿基因甲基转移酶 (PRMT) 调节癌症中至关重要的表观遗传过程.
- 在质瘤中,PRMT过度表达,与瘤进展和治疗耐药性相关.
研究的目的:
- 审查PRMT抑制剂在质瘤亚型中的转化和临床相关性.
- 突出最新的临床发展和正在进行的试验,用于质瘤的PRMT抑制剂.
- 提供最新的临床数据综合,讨论挑战,并建议未来用于质瘤治疗的PRMT抑制剂.
主要方法:
- 文献综述,重点是对质瘤中PRMT抑制剂的临床前研究.
- 在不同类型的质瘤中对PRMT抑制剂的当前临床数据的综合.
- 分析PRMT抑制剂临床转化中的挑战和机遇.
主要成果:
- 在质瘤中,PRMT在DNA修复和细胞信号通路中起着重要作用.
- 向PRMTs在破坏瘤生长和增强DNA损伤方面表现出临床前的有效性.
- PRMT 抑制剂可以改善质瘤对放射治疗和泰莫佐洛米德的敏感性.
结论:
- 在各种类型的质瘤中,PRMT抑制剂是一个有前途的治疗策略.
- 需要进一步的临床开发和研究,以优化PRMT抑制剂的整合到质瘤治疗方案中.
- 解决临床转化方面的挑战对于实现神经瘤学中PRMT抑制剂的全部潜力至关重要.
相关概念视频
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

